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Abstract
Background: During acute Human parvovirus B19 (B19) infection a transient reduction in blood haemoglobin 
concentration is induced, due to a 5-7 day cessation of red cell production. This can precipitate severe anaemia in 
subjects with a range of pre-existing conditions. Of the disease markers that occur during B19 infection, high IgM levels 
occur closest in time to the maximum reduction in haemoglobin concentration. Previous studies of the contribution of 
B19 to severe anaemia among young children in Africa have yielded varied results. This retrospective case/control 
study seeks to ascertain the proportion of severe anaemia cases precipitated by B19 among young children admitted 
to a Kenyan district hospital.
Methods: Archival blood samples from 264 children under 6 years with severe anaemia admitted to a Kenyan District 
Hospital, between 1999 and 2004, and 264 matched controls, were tested for B19 IgM by Enzyme Immunosorbent 
Assay and 198 of these pairs were tested for B19 DNA by PCR. 536 samples were also tested for the presence of B19 IgG.
Results: 7 (2.7%) cases and 0 (0%) controls had high B19 IgM levels (Optical Density > 5 × cut-off value) (McNemar's 
exact test p = 0.01563), indicating a significant association with severe anaemia. The majority of strongly IgM positive 
cases occurred in 2003.
10/264 (3.7%) cases compared to 5/264 (1.9%) controls tested positive for B19 IgM. This difference was not
statistically significant, odds ratio (OR) = 2.00 (CI95 [0.62, 6.06], McNemar's exact test p = 0.3018. There was no
significant difference between cases and controls in the B19 IgG (35 (14.8%) vs 32 (13.6%)), OR = 1.103 (CI95 [0.66,
1.89], McNemar's exact test, p = 0.7982), or the detection of the B19 DNA (6 (3.0%) vs 5 (2.5%)), OR = 1.2 (CI95 [0.33,
4.01], McNemar's exact test p = 1).
Conclusions: High B19 IgM levels were significantly associated with severe anaemia, being found only among the 
cases. This suggests that 7/264 (2.7%) of cases of severe anaemia in the population of children admitted to KDH were 
precipitated by B19. While this is a relatively small proportion, this has to be evaluated in the light of the IgG data that 
shows that less than 15% of children in the study were exposed to B19, a figure much lower than reported in other 
tropical areas.
Background
Severe anaemia (haemoglobin less than 50 g/l) is a major
cause of death among young children in malaria endemic
areas, including sub-Saharan Africa [1-3]. In such areas
the majority of children have mild to moderate anaemia
arising from factors which reduce red cell survival time
and/or inhibit erythropoiesis, including P falciparum
infection, iron deficiency, protein-energy malnutrition,
haemoglobinopathies and other infections including HIV
[4]. Parvovirus B19 (B19), which is common throughout
the world, has the potential to precipitate severe anaemia
in children with pre-existing moderate anaemia, particu-
larly those with significant haemolysis. The acute infec-
tion causes cessation of erythropoiesis for 5-7 days
arising from apoptosis of red cell precursors in the bone
marrow, which decreases the haemoglobin level for 1-2
weeks until bone marrow recovery [5]. After contact with
an infectious dose of the virus, rapid viral replication in
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erythroid progenitor cells results in a high level viraemia
which is terminated by the production of specific IgM
antibody beginning around day 9. A number of studies
have described high levels of IgM lasting for 1-2 weeks
(coinciding with the time of haemoglobin reduction)
[6,7]. Lower levels of IgM usually persist for 2-3 months
or more. After the high initial viral load lower levels of
B19 DNA can often be detected by nucleic acid amplifica-
tion techniques for 6 months or more, although in other
cases viral DNA drops below detectable levels within
weeks [8]. Thus, of the markers of B19 infection, high
IgM concentrations are most closely associated in time
with the period of reduced haemoglobin.
Recently B19 infection was found to be significantly
associated with severe anaemia among young children
living in a malaria-endemic region of Papua New Guinea
(PNG) [9]. Previous studies of the contribution of B19 to
severe anaemia among young children in Africa have
yielded varied results [2,3,10,11]. Here we present the
results of a retrospective case-control study investigating
the association between parvovirus B19 and severe anae-
mia in a malaria-endemic area of Kenya.
Methods
This retrospective case/control study used archived
blood samples stored at -80°C that had been collected
from all children admitted to Kilifi District Hospital,
Kenya between January 1999 and December 2004. Cases
were defined as children ≤ 6 years of age with a haemo-
globin concentration ≤ 50 g/l, and 50 were selected ran-
domly from each year 1999 to 2004. Controls with
haemoglobin > 50 g/l matched for age (+/- 6 months), sex
a n d  d a t e  o f  a d m i s s i o n  ( + / -  1  m o n t h )  w e r e  r a n d o m l y
selected from the hospital admissions (Table 1). A person
unaware of the clinical status performed the assays.
Haemoglobin was measured at the time of sample col-
lection using a Coulter counter (Beckman Coulter Inc,
Miami, USA). Stored plasma samples were tested for par-
vovirus B19 IgM and IgG at the same time using the
Biotrin Parvovirus B19 IgM and IgG Enzyme Immunoas-
say kits (Biotrin International Ltd, Dublin, Ireland). Sam-
ples in which red cells were incompletely removed during
the collection and storage process were included, other-
wise specimens were tested as per the kit manufacturer's
instructions. All case-control samples were tested for
IgM in duplicate, and the test repeated if the first two
results differed in outcome (positive, negative or equivo-
cal). For all further analyses equivocal readings were con-
sidered as negative. DNA was extracted from 50 μl of the
selected plasma samples into 200 μl final volume using
the ABI6100 system (Applied Biosystems, California). 5
μl aliquots of extracted DNA were then used in 25 μl PCR
reactions with IQ SYBR Green supermix (Bio-rad, Cali-
fornia). Primer concentration was optimized at 0.3
μmolar of each of primers B19 R and B19 F for detection
of Human parvovirus B19 genotypes 1-3 based on the
NS1 gene [12]. The Real-time reaction was performed in
a Bio-rad Chromo 4 cycler. Due to equipment breakdown
PCR results could only be obtained for 198 of the
matched pairs of samples. Extracted DNA from Parvovi-
rus B19 Standard (NIBSC, UK) was used for positive con-
trol and to generate a standard curve for quantitation.
Water was used for negative control and melting curve
analysis was performed.
Statistical analyses
In order to account for matching, the case-control data
were analysed with McNemar's exact test using StatXact
software (Cytel Inc, Cambridge, USA). The relationship
between  P. falciparum parasitaemia and B19 IgM was
analysed with Fisher's exact test usingGraphPad software
(GraphPad Software, Inc., La Jolla, USA.)
In calculating our sample size we assumed that around
4.5% of the non-severe anaemia studied samples would be
B19 IgM or DNA positive. This was thought to be a con-
servative estimate, being only one quarter of the figures
derived from our previous case/control study in PNG. On
this basis, a study of 300 cases matched to equal numbers
of controls would have 80% power to detect an odds ratio
for acute parvovirus infection in cases compared to con-
trols of 2.57 at a confidence level of >0.95. This power cal-
culation was done using SAM 2.1 computer program
[13].
This study was approved by the KEMRI/National Ethi-
cal Review Committee in Kenya and the University of
Sydney Human Research Ethics Committee in Australia,
reference 05-2006/3/9118.
Results
After samples (cases or controls) that were insufficient or
missing data were excluded, 264 matched pairs were
tested for the presence of B19 IgM. 198 of these matched
Table 1: Demographic characteristics of case/control population
Male Female Age(Mean)
Cases 53.6% 46.4% 23.29 months
Controls 53.6% 46.4% 23.28 monthsWildig et al. BMC Infectious Diseases 2010, 10:88
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pairs were tested for erythrovirus DNA and 271 cases and
265 controls were also tested for B19 IgG.
The frequency of B19 IgM positive samples in children
with severe anaemia was 10/264 (3.7%) compared to 5/
264 (1.9%) in the controls. This difference was not statis-
tically significant, odds ratio (OR) = 2.00 (CI95  [0.62,
6.06], McNemar's exact test p = 0.3018. Prevalence of B19
IgG increased with age (Table 2) (Figure 1). There was no
significant difference between matched cases and con-
trols in B19 IgG (35 (14.8%) vs 32 (13.6%)), OR = 1.103
(CI95 [0.66, 1.89], McNemar's exact test, p = 0.7982), or
the detection of B19 DNA (6 (3.0%) vs 5 (2.5%)), OR = 1.2
(CI95 [0.33, 4.01], McNemar's exact p = 1) (Table 3). Of
the samples from the matched pairs that were PCR posi-
tive, the quantitative PCR results (International Units/
reaction) for cases were 201, 5342, 6133, 9954, 1.8 × 104, 3
× 104; and for controls 32, 2071, 2520, 4384 and 2.48 × 104
(Table 4).
Table 2: IgM and IgG positivity by age in children admitted to Kilifi district hospital
Months of 
age
IgM positive IgG positive
Cases Controls Overall Cases Controls Overall
0-6 1/47
(2.1%)
0/40
(0%)
1/87
(1.1%)
7/43
(16.3%)
10/37
(27.0%)
17/80
(21.3%)
7-12 1/62
(1.6%)
0/68
(0%)
1/130
(0.8%)
6/57
(10.5%)
2/57
(3.5%)
8/114
(7.0%)
13-18 0/47
(0%)
2/43
(4.7%)
2/90
(2.2%)
2/39
(5.1%)
5/38
(13.2%)
7/77
(9.0%)
19-24 2/37
(5.4%)
1/32
(3.1%)
3/69
(4.3%)
6/29
(20.7%)
2/26
(7.7%)
8/55
(14.5%)
25-30 2/36
(5.6%)
0/40
(0%)
2/76
(2.6%)
6/29
(20.7%)
3/34
(8.8%)
9/63
(14.3%)
31-36 1/21
(4.8%)
0/20
(0%)
1/41
(2.4%)
1/20
(5.0%)
1/19
(5.3%)
2/39
(5.1%)
37-42 2/17
(11.8%)
0/20
(0%)
2/37
(5.4%)
4/17
(23.5%)
5/19
(26.3%)
9/36
(25%)
43-48 1/16
(6.3%)
2/12
(16.7%)
3/28
(10.7%)
3/15
(20%)
2/12
(16.7%)
5/27
(18.5%)
49-54 0/7
(0%)
0/9
(0%)
0/16
(0%)
0/6
(0%)
4/7
(57.1%)
4/13
(30.8%)
55-60 0/6
(0%)
1/5
(20%)
1/11
(9.1%)
2/5
(40%)
2/5
(40%)
4/10
(40%)
61-66 1/12
(8.3%)
0/10
(0%)
1/22
(4.5%)
4/12
(33.3%)
1/9
(11.1%)
5/21
(23.8%)
Total 11/308
(3.6%)
6/299
(2.0%)
17/607
(2.8%)
41/272
(15.1%)
37/263
(14.1%)
78/535
(14.6%)
Data.from samples collected in 1999-2004, including unpaired samples.Wildig et al. BMC Infectious Diseases 2010, 10:88
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In B19 IgM testing the highest Optical Density values
(i.e. Optical Density > 5 × cut-off OD) were all (n = 7)
found among the cases, with none (n = 0) among the con-
trols. The association between these high IgMs and
severe anaemia was statistically significant with McNe-
mar's exact two-tailed p = 0.0153. The odds ratio for this
effect is inestimable as the numbers of controls with high
IgM OD = 0.
Among the matched pairs in the study, 5 cases and 2
controls had a diagnosis of sickle cell disease. One of
these (a control) was B19 IgM positive. None of the chil-
d r e n  w i t h  s i c k l e  c e l l  d i s e a s e  w e r e  B 1 9  P C R  p o s i t i v e .
Results of blood slide microscopy for malaria parasites
were available for 256 of the matched pairs. Of these
there were 123 discordant pairs: 85 (69.1%) pairs where
the case was positive for P falciparum but the control was
not, and 38 (30.9%) pairs where the control was positive
for P falciparum but the case was not. Thus P falciparum
was significantly associated with severe anaemia (OR =
2.24 (CI95  [1.52, 3.37] McNemar's exact test p =
0.0000136)).
P. falciparum parasitaemia was not significantly associ-
ated with B19 IgM in either the cases or controls (Fisher's
exact test 2-tailed p = 0.7296 vs p = .0.6826). There was
no significant association between severe anaemia and
dual (both B19 IgM and P falciparum) positive samples (6
(2.3%) cases as compared with 3 (1.2%) controls. Odds
ratio = 2.00(CI95 [0.43, 9.23] McNemar's exact test p =
0.5078).
The incidence of B19 infection varied between years,
with an increase of positive B19 IgM results in the year
2003. In matched pairs from that year 7 (13.0%) of
severely anaemic children tested were positive for B19
IgM. 6 of the 7 high IgM results occurred in 2003 (Figure
2).
Discussion
In contrast to our previous study in PNG among children
with clinical malaria, where 30.2% of children with severe
anaemia and 12.4% of controls tested positive for B19
IgM, only a small proportion of these Kenyan samples
tested were positive for B19 IgM (3.7% of cases and 1.9%
of controls). This lower rate of infection in Kilifi is also
demonstrated in the IgG results, which show that of these
Kenyan children ≤ 6 years only 14.2% have previously had
a B19 infection as compared to 63% of children ≤ 5 years
in Wosera district, PNG. Possible reasons include differ-
ences in climate, socio - economic factors and genetic
factors. Furthermore the differences in the type of sam-
ples used should also be taken into account. In this study
the full range of hospital admissions included all seriously
ill children with a range of clinical problems, while in
PNG samples came from children with 'clinical malaria'
defined as fever with no obvious respiratory cause. It is
likely that the selection of children with a history of fever
increased the number of acute B19 infections in the PNG
samples.
The lower than expected frequency of infections
among the present study population meant that the anal-
ysis did not have the power to find a significant difference
between IgM positive rates in cases and controls with the
found odds ratio of 2. Thus, while there are more posi-
Table 3: Association of B19 IgM and PCR positivity among cases (having severe anaemia Hb ≤ 50 g/l) as compared to 
controls.
IgM IgM > 5 × COV PCR IgM+PCR*
Controls Controls Controls Controls
+-+-+-+-
Cases
(Hb ≤ 50 g/l)
+ 0 1 0 070603
- 52 4 902 5 751 8 711 9 4
Exact Odds Ratio 2.00
CI95 [0.62, 6.06]
+ Inf
CI95 [1.65, +Inf]
1.2
CI95 [0.33, 4.01]
3.00
CI95 [0.33, 77.48]
Exact McNemar 
test 2-sided p
p = 0.3018 p = 0.01563 p = 1 p = 0.625
Numbers refer to matched case-control control pairs.
* only double positive sample scored as positive.Wildig et al. BMC Infectious Diseases 2010, 10:88
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tives among cases for overall IgM+ and PCR+ these dif-
ferences did not reach statistical significance. However in
spite of the low numbers of B19 infections, a high B19
IgM level (Optical Density> 5 × cut-off Value) is signifi-
cantly associated with severe anaemia. High IgM levels
are most likely to be measured around the time of haemo-
globin reduction, and therefore have the strongest associ-
ation with severe anaemia. This association suggests that
in other places where B19 infections are more common
among young children (e.g. Eritrea) [14], the contribution
of B19 to severe anaemia would be greater. Also, as the
incidence of B19 infections fluctuates over time, the clus-
ter of B19 infections in 2003 reveals the potential impact
of B19 as an intermittent cause of severe anaemia in this
area of sub-Saharan Africa. Further studies are required
to estimate the frequency of B19 infections among young
children in areas where severe anaemia is a major prob-
lem.
In the current study P. falciparum infection is shown to
be a cause of severe anaemia in this area, as has been doc-
umented previously [2], however we did not find a signif-
icant association between the prevalence of B19 IgM
positivity and P. Falciparum parasitaemia in children pre-
senting with severe anaemia.
Table 4: Data from the 429 samples from among the matched pairs on which all three assays (B19 IgM, IgG and DNA) were 
performed
Cases PCR Positive Number (IU/Reaction) PCR Negative
B19 IgM-, IgG- 3 (201, 6133, 9954) 182
B19 IgM +, IgG- 1 (1.8 × 104)1
B19 IgM +, IgG+ 2 (3 × 104, 5342) 1
B19 IgM-, IgG+ 0 28
Controls
B19 IgM-, IgG- 4 (2.48 × 104, 2071, 2520, 4384) 177
B19 IgM+, IgG- 0 3
B19 IgM+, IgG+ 1 (32) 1
B19 IgM-, IgG+ 0 26
Figure 1 Percentage of Kenyan children with B19 IgG by age 
(Polynomial 4th order regression curve).
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Figure 2 Percentage of children with B19 IgM in each year tested. 
Error bars indicate 95% confidence interval.
0
2
4
6
8
10
12
1998 1999 2000 2001 2002 2003 2004 2005
Year
P
e
r
c
e
n
t
a
g
eWildig et al. BMC Infectious Diseases 2010, 10:88
http://www.biomedcentral.com/1471-2334/10/88
Page 6 of 6
Conclusions
High B19 IgM levels were significantly associated with
severe anaemia, being found only among the cases. This
suggests that at least 2.7% of cases of severe anaemia in
the population of children admitted to Kilifi District Hos-
pital were precipitated by B19. While this is a relatively
small proportion, this has to be evaluated in the light of
the IgG data which shows that less than 15% of children
in the study had contracted B19, a figure much lower
than reported in other tropical areas.
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